Physician profile
Andrew Pearson
NPI 1316161458
$165,962.55
in general payments reported to CMS, 2019-2025
46 companies · $85K in 2025
The $85K reported for 2025 was more than what 98% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,938 · 2020: $1,471 · 2021: $2,626 · 2022: $2,977 · 2023: $3,266 · 2024: $69K · 2025: $85K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $127K · Food and Beverage: $16K · Consulting Fee: $8,340 · Travel and Lodging: $6,025 · Education: $19.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $127,048.86 |
| Food and Beverage | $15,517.76 |
| Consulting Fee | $8,340.00 |
| Travel and Lodging | $6,025.01 |
| Education | $19.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $87,702.92 | 2023-2025 | Voquezna |
| Janssen Biotech, INC. | $50,032.96 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Janssen Scientific Affairs, LLC | $10,147.54 | 2021-2025 | Tremfya, Stelara |
| Abbvie INC. | $7,523.97 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,828.71 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Takeda Pharmaceuticals U.S.A., INC. | $1,303.30 | 2019-2025 | Entyvio, Gattex |
| Gilead Sciences, INC. | $900.30 | 2019-2025 | |
| Ironwood Pharmaceuticals, INC | $605.56 | 2019-2024 | Linzess |
| Pfizer INC. | $570.03 | 2019-2025 | |
| Nestle Healthcare Nutrition INC. | $561.74 | 2020-2023 | |
| Genzyme Corporation | $483.53 | 2023-2025 | |
| Celgene Corporation | $436.96 | 2021-2024 | Zeposia |
| Intercept Pharmaceuticals, INC. | $317.62 | 2019-2025 | Ocaliva |
| Ardelyx, INC. | $315.10 | 2022-2025 | Ibsrela |
| Daiichi Sankyo INC. | $309.08 | 2020-2025 | Injectafer |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $263.53 | 2019-2023 | Rebyota |
| Allergan, INC. | $249.56 | 2019 | |
| Lilly USA, LLC | $241.81 | 2023-2025 | Omvoh |
| Qol Medical, LLC | $225.17 | 2021-2025 | Sucraid, Sucraid |
| Regeneron Healthcare Solutions, INC. | $222.39 | 2023-2025 | Dupixent |
| Boston Scientific Corporation | $217.17 | 2019-2024 | Resolution 360 Clip |
| Madrigal Pharmaceuticals | $206.17 | 2025 | Rezdiffra |
| Medtronic, INC. | $176.78 | 2025 | Interstim |
| Merck Sharp & Dohme LLC | $152.89 | 2019-2024 | Dificid |
| Axonics, INC. | $133.54 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $112.08 | 2023 | |
| Redhill Biopharma INC. | $102.95 | 2020-2023 | Talicia |
| Amgen INC. | $83.86 | 2020-2023 | Avsola, Amjevita |
| Alnylam Pharmaceuticals INC. | $72.08 | 2023-2024 | Givlaari |
| Aimmune Therapeutics, INC. | $61.49 | 2025 | Zenpep |
| Ipsen Biopharmaceuticals, INC | $60.68 | 2024-2025 | Iqirvo |
| Alfasigma USA, INC. | $47.17 | 2020-2021 | |
| Braintree Laboratories, INC. | $44.70 | 2020-2021 | |
| Olympus America INC. | $42.06 | 2024 | Evis Exera III Colonovideoscope, Gastrointestinal Videoscope, Evis X1 Video System Center |
| Novo Nordisk INC | $33.32 | 2025 | Wegovy |
| Echosens North America, INC. | $31.59 | 2019 | |
| Thd America, INC. | $31.26 | 2023-2024 | |
| Enterra Medical, INC. | $20.55 | 2022 | |
| Ucb, INC. | $17.44 | 2019 | |
| Laborie Medical Technologies Corp. | $17.28 | 2023 | |
| Intra-Sana Laboratories | $16.07 | 2021 | |
| Shire North American Group INC | $15.66 | 2019 | |
| Celltrion USA INC. | $14.54 | 2025 | Vegzelma |
| Endogastric Solutions, INC | $6.32 | 2024 | Esophyx |
| Travere Therapeutics, INC. | $3.12 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Pearson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.